Theriva Biologics shares are trading higher after the company announced it was selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics shares rose after being selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.
October 31, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theriva Biologics shares increased following the announcement that the company is a finalist for Merck KGaA's EMEA Advance Biotech Grant.
Being selected as a finalist for a prestigious grant can boost investor confidence and increase the perceived value of Theriva Biologics, leading to a rise in stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90